Filing Details
- Accession Number:
- 0001209191-19-007568
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-05 19:57:56
- Reporting Period:
- 2019-02-01
- Accepted Time:
- 2019-02-05 19:57:56
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1445283 | Proteostasis Therapeutics Inc. | PTI | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1534200 | Meenu Chhabra | C/O Proteostasis Therapeutics, Inc. 80 Guest Street, Suite 500 Boston MA 02135 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-02-01 | 46,875 | $0.00 | 97,093 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-02-04 | 16,478 | $2.99 | 80,615 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2019-02-01 | 46,875 | $0.00 | 46,875 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of PTI common stock.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and were made in order to pay the tax liability arising from the vesting of restricted stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.96 to $3.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The restricted stock units vested in full on February 1, 2019.